SillaJen Pays $150M For Tumor Treatment Firm

Law360, New York (November 26, 2013, 8:47 PM EST) -- South Korea-based biotherapeutics and contract research company SillaJen Inc. will acquire San Francisco clinical-stage biotechnology firm Jennerex Inc. for about $150 million, SillaJen said Tuesday, in a merger that would bring together two companies that have previously partnered in the quest against cancer.

The all-cash deal, which is expected to close in the first quarter of 2014, merges two companies that have been clinical research partners dating back to 2007, according to a SillaJen statement released Tuesday. Upon completion of the transaction, Jennerex will keep its...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.